Savant Capital LLC Buys 117 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Savant Capital LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 514 shares of the biopharmaceutical company’s stock after acquiring an additional 117 shares during the quarter. Savant Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $451,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of REGN. Mission Wealth Management LP lifted its holdings in Regeneron Pharmaceuticals by 4.2% during the fourth quarter. Mission Wealth Management LP now owns 471 shares of the biopharmaceutical company’s stock valued at $414,000 after purchasing an additional 19 shares in the last quarter. Auxano Advisors LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth $208,000. Certuity LLC increased its stake in Regeneron Pharmaceuticals by 66.0% in the 4th quarter. Certuity LLC now owns 1,104 shares of the biopharmaceutical company’s stock worth $970,000 after buying an additional 439 shares in the last quarter. Norden Group LLC bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $230,000. Finally, Kestra Private Wealth Services LLC raised its holdings in Regeneron Pharmaceuticals by 19.7% during the fourth quarter. Kestra Private Wealth Services LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $1,556,000 after acquiring an additional 292 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $957.00 on Monday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33. The firm has a market cap of $105.04 billion, a price-to-earnings ratio of 28.27, a PEG ratio of 2.74 and a beta of 0.17. The business’s fifty day simple moving average is $943.75 and its two-hundred day simple moving average is $897.24. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the company earned $10.96 EPS. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

Insider Activity

In related news, EVP Marion Mccourt sold 358 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $967.50, for a total value of $346,365.00. Following the transaction, the executive vice president now owns 13,431 shares of the company’s stock, valued at $12,994,492.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the sale, the director now directly owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Marion Mccourt sold 358 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $967.50, for a total transaction of $346,365.00. Following the transaction, the executive vice president now directly owns 13,431 shares in the company, valued at approximately $12,994,492.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 9,095 shares of company stock valued at $8,729,766. Corporate insiders own 8.83% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Barclays increased their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective on the stock. Truist Financial reissued a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. UBS Group raised their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Finally, TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $981.71.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.